By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Seaside Therapeutics 

700 Technology Square
Suite 201
Cambridge  Massachusetts  02139  U.S.A.
Phone: n/a Fax: n/a



Company News
Roche (RHHBY) Backs Out on Seaside Therapeutics Drug Trial for Fragile X. Parents Dismayed 6/10/2013 7:59:45 AM
Seaside Therapeutics' Drug May Help Some Autism Cases 9/20/2012 8:18:12 AM
Seaside Therapeutics Named a “Fierce 15” Biotech Company for 2012 9/19/2012 9:51:43 AM
Roche (RHHBY), Seaside Therapeutics to Research Autism Treatments 6/19/2012 6:34:06 AM
Seaside Therapeutics Announces Issuance of Key Patent for Lead Autism Candidate STX209 3/28/2012 7:15:59 AM
Seaside Therapeutics Presents Data on Potential Pharmaceutical Treatment for Improving Social Impairment in Autism Spectrum Disorders at 42nd Autism Society National Conference 7/11/2011 10:02:40 AM
Seaside Therapeutics Initiates Phase 2b Study of STX209 in Autism Spectrum Disorders 6/21/2011 8:41:08 AM
Seaside Therapeutics Initiates Pivotal Phase 3 Study of STX209 in Fragile X Syndrome 6/2/2011 10:38:41 AM
Seaside Therapeutics Publishes Review of Advances in the Treatment of Fragile X Syndrome in American Chemical Society Chemical Neuroscience 5/18/2011 9:50:18 AM
Seaside Therapeutics Reports Positive Data from Phase 2 Study of STX209 in Autism Spectrum Disorders 9/9/2010 11:25:06 AM